Brian Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, and Christopher Wallis, MD, PhD, University of Toronto, discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data available for pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma.